-
1دورية أكاديمية
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Supplementary Figures S1 to S5, with each figure followed by its corresponding legend in the next page
الإتاحة: https://doi.org/10.1158/2159-8290.25183895.v1Test
https://figshare.com/articles/journal_contribution/Supplementary_Figures_S1-S5_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183895Test -
2دورية أكاديمية
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Demographics and details of treatment in patients who continued ICI progression (n=38)
الإتاحة: https://doi.org/10.1158/2159-8290.25183886.v1Test
https://figshare.com/articles/journal_contribution/Table_S2_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183886Test -
3صورة
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Impact of radiotherapy. A, Patient progressing on nivolumab received reirradiation, following which further progression prompted the addition of ipilimumab. This was followed by radiologic flare, and continued treatment with supportive care led to delayed response. B, Impact of reirradiation on survival. C, Impact of additional reirradiation (RT) in patients who received nivolumab and ipilimumab. D, Relative contribution of the radiation-induced indel signature (ID8) in RRD-HGG and controls from the GLASS cohort (Methods). E, Paired analysis of the relative contribution of ID8 before (at diagnosis) and after the second progression (post primary radiation, and then immunotherapy at first progression) in five patients.
الإتاحة: https://doi.org/10.1158/2159-8290.25183901.v1Test
https://figshare.com/articles/figure/Figure_5_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183901Test -
4صورة
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Patients treated with nivolumab and trametinib ( n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B , Swimmer's plot summarizing events in each patient. C , The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
الإتاحة: https://doi.org/10.1158/2159-8290.25183904.v1Test
https://figshare.com/articles/figure/Figure_4_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183904Test -
5صورة
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
الإتاحة: https://doi.org/10.1158/2159-8290.25183898.v1Test
https://figshare.com/articles/figure/Figure_6_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183898Test -
6صورة
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Genomic features of patients with RRD-HGG treated with salvage therapies ( n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).
الإتاحة: https://doi.org/10.1158/2159-8290.25183910.v1Test
https://figshare.com/articles/figure/Figure_2_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183910Test -
7صورة
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Patients receiving dual-checkpoint inhibition with ipilimumab and anti–PD-1 after failing ICI monotherapy ( n = 24). A, Swimmer's plot for each patient, showing the best documented radiologic response at any time during treatment. Inset, representative radiologic image showing response to dual-checkpoint inhibition. B, Progression-free (PFS2) and overall survival (OS2). C, Normalized CTLA4 expression counts generated using NanoString platform (Methods) for in-house non-RRD, nonmalignant brain controls, and at different time points for RRD-HGG. D, Paired analysis of normalized CTLA4 expression counts before and after anti–PD-1 therapy for the same patient. E, Toxicities (≥CTCAE grade 3) observed in CMMRD and Lynch syndrome patients on dual ICI.
الإتاحة: https://doi.org/10.1158/2159-8290.25183907.v1Test
https://figshare.com/articles/figure/Figure_3_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183907Test -
8صورة
المؤلفون: Anirban Das, Nicholas R. Fernandez, Adrian Levine, Vanessa Bianchi, Lucie K. Stengs, Jiil Chung, Logine Negm, Jose Rafael Dimayacyac, Yuan Chang, Liana Nobre, Ayse B. Ercan, Santiago Sanchez-Ramirez, Sumedha Sudhaman, Melissa Edwards, Valerie Larouche, David Samuel, An Van Damme, David Gass, David S. Ziegler, Stefan S. Bielack, Carl Koschmann, Shayna Zelcer, Michal Yalon-Oren, Gadi Abede Campino, Tomasz Sarosiek, Kim E. Nichols, Rebecca Loret De Mola, Kevin Bielamowicz, Magnus Sabel, Charlotta A. Frojd, Matthew D. Wood, Jason M. Glover, Yi-Yen Lee, Magimairajan Vanan, Jenny K. Adamski, Sebastien Perreault, Omar Chamdine, Magnus Aasved Hjort, Michal Zapotocky, Fernando Carceller, Erin Wright, Ivana Fedorakova, Alexander Lossos, Ryuma Tanaka, Michael Osborn, Deborah T. Blumenthal, Melyssa Aronson, Ute Bartels, Annie Huang, Vijay Ramaswamy, David Malkin, Adam Shlien, Anita Villani, Peter B. Dirks, Trevor J. Pugh, Gad Getz, Yosef E. Maruvka, Derek S. Tsang, Birgit Ertl-Wagner, Cynthia Hawkins, Eric Bouffet, Daniel A. Morgenstern, Uri Tabori
مصطلحات موضوعية: Cancer, Tumor Biology, Cancer Detection and Diagnosis, Therapeutic Research and Development, Immuno-oncology, Clinical Research and Trials, Biomarkers, Clinical-stage Research, CNS Cancers, Gliomas, Glioblastomas, Immunotherapy, Checkpoint blockade, Pediatric Cancers, Translational Research, Tumor Evolution, Tumor Microenvironment
الوصف: Patients with RRD-HGG treated with ICI ( n = 75). A, Cohort characteristics. B, Flow of patients with RRD-HGGs treated with ICIs and salvage regimens. MEK-i, MEK inhibitor. C, Progression-free (PFS1) and overall survival (OS1) on anti–PD-1/PDL1 monotherapy. D, Overall survival (OS2) for 55 patients progressing on monotherapy stratified by continued ( n = 38) or no ICI ( n = 17). PPAP, polymerase proofreading associated polyposis syndrome; CMMRD, constitutional mismatch repair deficiency syndrome.
الإتاحة: https://doi.org/10.1158/2159-8290.25183913.v1Test
https://figshare.com/articles/figure/Figure_1_from_Combined_Immunotherapy_Improves_Outcome_for_Replication-Repair-Deficient_RRD_High-Grade_Glioma_Failing_Anti_PD-1_Monotherapy_A_Report_from_the_International_RRD_Consortium/25183913Test -
9
المصدر: Tidsskrift for Den norske legeforening.
مصطلحات موضوعية: Male, Knee Joint, Humans, Pain, General Medicine, Ankle, Physical Examination, Ankle Joint
الوصف: A previously healthy boy presented to the healthcare services on several occasions with pain in his knee, ankle and foot. Clinical examinations and additional diagnostic testing initially revealed no red flags, but after 5 months, the boy was diagnosed with a serious and unexpected condition.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7bb868a00c65fa02dce1853957633b4Test
https://doi.org/10.4045/tidsskr.21.0647Test -
10
المؤلفون: Jonathan Kjær, Grønbæk, Aske Foldbjerg, Laustsen, Sebastian, Toescu, Barry, Pizer, Conor, Mallucci, Kristian, Aquilina, Emanuela, Molinari, Magnus Aasved, Hjort, Lingvita, Gumbeleviciene, Peter, Hauser, Beatrix, Pálmafy, Kirsten, van Baarsen, Eelco, Hoving, Julian, Zipfel, Christoffer, Ehrstedt, Pernilla, Grillner, Michael Thude, Callesen, Radek, Frič, Morten, Wibroe, Karsten, Nysom, Kjeld, Schmiegelow, Astrid, Sehested, René, Mathiasen, Marianne, Juhler
المصدر: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 38(8)
مصطلحات موضوعية: Postoperative Complications, Mutism, Cerebellar Diseases, Risk Factors, Humans, Speech, Infratentorial Neoplasms, Prospective Studies, Cerebellar Neoplasms, Child, Functional Laterality
الوصف: Cerebellar mutism syndrome (CMS) is a severe neurological complication of posterior fossa tumour surgery in children, and postoperative speech impairment (POSI) is the main component. Left-handedness was previously suggested as a strong risk factor for POSI. The aim of this study was to investigate the relationship between handedness and the risk of POSI.We prospectively included children (aged 18 years) undergoing surgery for posterior fossa tumours in 26 European centres. Handedness was assessed pre-operatively and postoperative speech status was categorised as either POSI (mutism or reduced speech) or habitual speech, based on the postoperative clinical assessment. Logistic regression was used in the risk factor analysis of POSI as a dichotomous outcome.Of the 500 children included, 37 (7%) were excluded from the present analysis due to enrolment at a reoperation; another 213 (43%) due to missing data about surgery (n = 37) and/or handedness (n = 146) and/or postoperative speech status (n = 53). Out of the remaining 250 (50%) patients, 20 (8%) were left-handed and 230 (92%) were right-handed. POSI was observed equally frequently regardless of handedness (5/20 [25%] in left-handed, 61/230 [27%] in right-handed, OR: 1.08 [95% CI: 0.40-3.44], p = 0.882), also when adjusted for tumour histology, location and age.We found no difference in the risk of POSI associated with handedness. Our data do not support the hypothesis that handedness should be of clinical relevance in the risk assessment of CMS.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::5490c040f0cc9640b44a25eb9b026a37Test
https://pubmed.ncbi.nlm.nih.gov/35759029Test
